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Tumor-specific transplantation antigens (TSTA)' as target structures for a potent
autologous immune rejection response have been regularly found in chemically and
UVinduced mouse tumors . These antigens were defined by in vivo crossprotection
experiments (1, 2) . There is experimental evidence suggesting that TSTA are recog-
nized by cytolyticT lymphocytes (CTL) in the course of immunologicallymediated
tumor regression (3, 4) . Serological probes against TSTA could not be obtained .
Recently, the isolation of methylcholanthrene-induced TSTA was reported (5) . In
the search for similar antigens on humanmelanoma cells and on otherhuman cancers,
severalgroups derived tumor-reactive CTL clones from the peripheral blood oftumor
patients (6-8) (for review see reference 9) . Improved culture techniques, meanwhile,
facilitate a more systematic production of stable tumor-reactive CTL clones (10) .
To date, nothing is known about the nature of their target antigens .
Two principal target structures forCTL on autologous target cells are character-
ized at a molecular level . First, fragments ofviral antigens or mutated self proteins
are recognized in association with MHC molecules (11-13) and, second, mutated
MHC molecules themselves can be the target molecules (14) . So far, the mechanism
ofCTL recognition of autologoushuman tumor cellshas been investigated by inhi-
bition experimentswith mAbs against common TCR structures and framework de-
terminants of HLA molecules . For a subset of cytotoxic lymphocyte clones, TCRs
andHLA class I molecules were clearly involved in target cell recognition (for re-
view see reference 9) .
In continuation ofearlierwork (7), we recently generatedCTLclones from a mela-
noma patient (AV) by mixed lymphocyte tumor cell culture (MLTC) and subse-
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quent cloning of responder lymphocytes using autologous tumor cellsas stimulators
(15). The CTL clones lysed the autologous melanoma cellsbut not autologous EBV
transformed B cells, and none of the allogeneic targets within a panel of -20 tumor
lines of various histologic origins. No difference in tumor antigen expression was
detected on autologous melanoma clones. To find out ifthe CTL clones were directed
against different antigens, immunoselection experiments were carried out with two
ofthe CTL clones (CTL2/9 and CTL5/57). Some of the surviving melanoma clones
were resistant to lysis by the CTL clones used for immunoselection, but were lysed
by other autologous CTL clones. Thus, we concluded that at least three stable CTL-
defined antigens are simultaneously expressed on SK-MEL-29 cells. These findings
parallel those obtained with the methylcholanthrene-induced mouse mastocytoma
P815 where multiple simultaneously expressed tumor antigens were also detected
in immunoselection experiments (3).
In the human melanoma line SK-MEL-29, antigen A is recognized by CTL2/9
and antigen B by CTL5/57 . Antigen C is recognized by the other CTL clones in-
cluded in our recent study (CTL3/7, CTL3/9, and CTL5/76) and may be dissected
into further specificities by immunoselection experiments. The lysis by all CTL clones
could be inhibited by the mAb W6/32 (16), which is directed against a monomorphic
determinant of HLA class I molecules. This suggests that HLA class I molecules
are involved in antigen recognition by the AV CTL. Here we demonstrate experimental
evidence that all previously defined AV melanoma antigens are presented to autolo-
gous CTL in association with HLA-A2.
Materials and Methods
Patient.
￿
Patient AV, a 36-yr-old caucasian male, developed metastatic malignant mela-
noma in 1975. He underwent resections of extensive metastatic melanoma of axillary,
supraclavicular, and cervical lymph nodes in 1975 and in 1978. Since that time he is free
ofdetectable disease. In 1975 a melanoma cell line (SK-MEL-29) was derived from a metastatic
lesion. From 1976 to 1978, the patient's lymphocytes were found to be strongly cytotoxic for
autologous cultured melanoma cells (17). Later, only minimal lymphocyte cytoxicity for au-
tologous melanoma cells was detectable. The patient's HLA-A,-B,-C phenotype is A2, A28,
B44 (Bw4), Bw50 (Bw6), Cw5, Cw6.
Cell Lines.
￿
The melanoma cell line SK-MEL-29 (17) was a generous gift ofDr. L. J. Old
(Memorial Sloan-Kettering Cancer Center, New York). The derivation of melanoma clones
from this line by limiting dilution and in vitro immunoselection is explained in Fig. 1. The
human melanoma line MZ-2-MEL was described in reference 10. AK-EBV and AVEBV
are EBVtransformed lymphoblastoid (EBVB) cell lines established from a healthy donor
(AK) and from the melanoma patient (AV), respectively. Tumor cell lines were maintained
in DME (Gibco Laboratories, Grand Island, NY) containing 10 mM Hepes buffer, L-arginine
(116 Mg/Ml), L-asparagine (36 mg/ml), L-glutamine (216 mg/ml), penicillin (10 IU/ml), strep-
tomycin (100 14g/ml), and 10% FCS. This medium is further referred to as Ma. EBVB lines
were cultured in RPMI 1640 (Mb), supplemented as described for Ma. Cell cultures were
kept in a water-saturated atmosphere with 5% C02 at 370C .
When indicated, human rIFN-,y (Genentech, San Francisco, CA) was added to the culture
medium at a concentration of 100 U/ml 4 d before cytolysis assays to increase the level of
HLA expression on target cells.
Maintenance of CTL Clones.
￿
The derivation ofautologous CTL clones directed against SK-
MEL-29 was described previously (15). CTL were maintained in long-term culture by trans-
ferring (every 4-7 d) 2-3 x 105 CTL to 2-ml cultures containing 5 x 104 autologous mela-
noma cells as stimulators and 2 x 105 AK EBV cells as feeders in 24-well tissue culture plates.
Both stimulator and feeder cells were irradiated before CTL culture with 100 Gy from aWOLFEL ET AL.
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137CS source. As culture medium (M'), we used RPMI 1640 medium supplemented as de-
scribed above, but with 10% human serum and human rIL-2 (25 U/ml) (a generous gift
from Biogen S. A., Geneva, Switzerland) (18).
Derivation of CTL Clones.
￿
MLTC experiments and cloning ofresponder lymphocytes and
testing for cytolytic activity were performed as described previously (10, 15). PBL were sepa-
rated from heparinized bloodofthe patient AV by centrifugation on a Ficoll-Paque gradient.
PBL (106) were cocultured with 105 melanoma cells (clone SK-MEL-29.1.29, irradiated with
100 Gy from a 137CS source) in 2 ml of medium M` containing 10°70 human serum on 24-
well plates (Greiner, Nurtingen, FRG). Human rIL-2 was added from day 3 on at 25 U/ml.
After 7 d, MLTC responder lymphocytes were seeded at 1 cell/well in round-bottomed
96-well microtiter plates (Greiner) preseeded with autologous melanoma cells (3 x 103/well,
irradiated) as stimulators and AK EBV (104/well, irradiated) as feeder cells in a totalvolume
of 200,ul of medium M` with human serum and IL-2. 1 wk later (day 7), 100 pl of superna-
tant was removed from each well and replaced by 100 jul M` (with IL-2) with fresh stimu-
lator and feeder cells. On day 14, microcultures were transferred to flat-bottomed 96-well
microtiter plates (Greiner) (total culture volume, 300 pl) and tested on day 21 in an initial
screening for cytolytic activity on autologous melanoma cells and K562 as described below.
Lymphocyte colony growth was followed under microscope from day 12 on. Exceptionally
fast-growing colonies were transferred to Linbro wells immediately.
AssayforCytolytic Activity.
￿
Standard 51Cr release cytotoxicity assays were used (19). Target
cells were incubated at 10' cells/ml in FCS for 45 min at 37°C with 200 uCi/ml of Na("Cr)04
(Institut des Radioelements, Fleurus, Belgium), washed three times, and resuspended in
medium Ma at 104 cells/ml. CTL were serially diluted in duplicates in 100 Al of medium
Ma in conical 96-well microtiter plates. After adding 100 pl of labeled target cell suspension,
plates were incubated for 4 h at 37°C in a 5% C02 atmosphere. The assays were terminated
by centrifugation at 200 g for 5 min and collection of 100 Al supernatant for counting in
a gamma counter. Percent specific 51Cr release was calculated with the formula: percent
specific "Cr release = 100 x (experimental release - spontaneous release)/(maximum re-
lease - spontaneous release). Spontaneous 51Cr releases were between 10 and 25% of the
total label incorporated in the cells.
MLTC-derived responder colonies were initially screened in a microcytotoxicity assay. Care-
fully mixed cell suspensions in microtiter plates were split in 60-Al aliquots and added to
labeled targets in microtiter test plates to a final volume of 200 AI. The plates were processed
as described above.
Immunoselection with CTL Clones.
￿
Immunoselection experiments were designed according
to Maryanski and Boon (20) and were performed in our previous study (15).
Serological Reagents.
￿
Human HLA-reactive pregnancy sera were identified according to
standard procedures (21). The mAbs used in this study are listed in Table I. They were pur-
chased from the American Type Culture Collection (Rockville, MD), except for the mAb
4E, which is a kind gift of Dr. S. Y. Yang (Memorial Sloan-Kettering Cancer Center). All
mAbs were used as ascites with an approximate protein concentration of 15-20 mg protein
per ml.
Inhibition of Cytolysis.
￿
5'Cr-labeled target cells (103/well) were admixed in duplicates to
serial dilutions of antisera or mAbs in medium Ma in conical 96-well microtiter plates. Then,
CTL (3 x 104/well) were added in the same medium to give a final volume of 200 141/well.
After a 4-h incubation period at 37°C in a 5% C02 atmosphere, plates were harvested and
processed as described for cytolysis assays. Controls always included incubation of antisera
or mAbs at the maximum concentrations with targets alone to exclude antibody-dependent
mechanisms of cell lysis in the absence of CTL.
Flow Cytometric Analysis.
￿
Tumorcells were incubated with murine mAbs at saturating con-
centrations for 30 min on ice, washed, and stained with polyclonal goat anti-mouse F(ab')2
antibody fragments coupled with FITC (Coulter Electronics Inc., Hialeah, FL) for another
30 min on ice. Samples were analyzed on an EPICS C cell sorter (Coulter Electronics Inc.).
DNA Extraction andSouthern Blot Hybridization.
￿
High-molecular weight DNA was prepared
from tumor cells and CTL as described elsewhere (26). CTL were separated from cell debris
on a Ficoll-Paque gradient (Pharmacia Fine Chemicals, Uppsala, Sweden) before DNA ex-
traction. Hybridization with bacteriophage M13 was performed as detailed in reference 27.800
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Immunoprecipitation and IEF Analysis.
￿
Cells were metabolically labeled with [35S]methio-
nine. Preparation of NP-40 extracts and immunoprecipitation with W6/32 (16) and forma-
lin-fixed Staphylococcus aureus Cowan strain 1 was described earlier (28). IEF of the immuno-
precipitates was carried out in polyacrylamide gels according to the 10th International
Histocompatibility Workshop protocol (29). HLA antigens of the cell lines were assigned
by IEF band patterns in comparison with the standardized IEF band patterns of HLA class
I alleles of the 10th International Histocompatibility Workshop (29).
Results
Inhibition of Cytolysis by Human Anti-HLA-A2 Sera.
￿
In mouse model systems inhi-
bition of CTL lysis by anti-MHC antibodies proved to be a reliable approach in
identifying MHC molecules as restriction elements (30-32). The application of this
approach to human systems is hampered by a lack of allele-specific anti-HLA mAbs.
Therefore, we primarily used HLA-reactive sera from pregnant women. About 10%
ofpregnancy sera exhibit mono- or multispecific HLA reactivity. Among these, anti-
HLA-A2 sera are found most frequently and are predominant among monospecific
sera (33). Since AV cells express HLA-A2, we tested monospecific anti-HLA-A2 sera
from pregnant women in inhibition experiments with the effector CTL2/9 and the
target melanoma clone SK-MEL-29 .1. At a 16% serum concentration, 4 of 10 anti-
HLA-A2 sera reduced the CTL lysis by >60% in 4-h "Cr release assays at a 30 :1
E/T ratio (see example in Fig. 2).
Absorption of an HLA-A2-reactive serum with an excess of mouse mastocytoma
P1.HTR cells (34) that expressed an HLA-A2 gene after transfection (35, 36) abol-
ished its inhibiting effect (PI.HTRA2 cells were a kind gift fromJ. Maryanski, Ludwig
TABLE I
mAbs Used in Inhibition Experiments and FAGS Analysis
mAb
￿
Antigenic specificity
￿
Isotype
￿
Reference
W6/32
￿
Class I HLA
￿
IgG2a
￿
16
HB55
￿
Class II HLA
￿
IgGl
￿
22
MA2.1
￿
HLA-A2, HLA-1317
￿
IgGl
￿
23
PA2.1
￿
HLA-A2, HLA-A28
￿
IgGl
￿
24
4E HLA-13
￿
IgG2a 25
SK-MEL-29(A+B+C+)
coning
SK-MEL-29.1 (A+B+C+)
SK-MEL-29.1.106 SK-MEL-29.1,1¢
(A
-B+C+) (A+B-C+)
SK-MEL-29.],22(,29
(HLA-A2neg.)
FIGURE 1.
￿
AV melanoma clones derived by limiting dilution and
immunoselection with autologous CTL clones (15).Institute for Cancer Research, Lausanne, Switzerland). Absorption with untrans-
fected P815 cells did not influence the inhibition (Fig. 2). This indicated that the
blocking ability of the serum was due to its HLA-A2 reactivity.
Inhibition ofCytolysis by Anti-HLAA2 mAbs.
￿
A number ofHLA-A2-reactive mAbs
have been isolated. Two ofthem, MA2.1 (23) and PA2.1 (24), were used as ascites
for inhibition experiments in this study (Table 1). MA2.1 recognizes an antigenic
determinant shared by HLA-A2 and -B17 (23). PA2.1 is directed against a specific
determinant shared by HLA-A2 and a variant of HLA-A28 (37) that is different
from the epitoperecognized byMA2.1 (38). MA2.1 could efficientlyinhibitthe lysis
by all five previously established AV CTL clones (15) (Fig. 3 for CTL2/9,5/57,
and 5/76). PA2.1 only reproducibly inhibited the lysis by CTL clone CTL2/9. This
indicatedthe involvement ofHLA-A2intarget recognition byall ofthe CTL clones.
Tumor cell variants SK-MEL-29.1.109 and SK-MEL-29.1.14 were derived by im-
munoselectionexperimentswithCTL2/9 and CTL5/57 (Fig. 1). Thesevariantswere
resistant to lysis by the selecting CTL but still lysed by others (15; and Fig. 4 A).
As demonstrated by FRCS analysis with the anti-HLA-A2 antibodies MA2.1 and
PA2.1, these antigen-negative variants still expressed HLA-A2 (Fig. 5).
Lack ofHLAA2Expression on AVMelanoma CellsAbrogates Cytolysis by Autologous CTL
Clones ofDifferent Specicities. Invitro immunoselection experiments were previously
performed with CTL2/9 and CTL5/57 (15; and Fig. 1). Cells ofthe AV melanoma
clone SK-MEL-29.1 were irradiated with 1,000 rad to increase the probability of
genetic lesions causing a loss ofexpression ofCTL-defined antigens. These target
cells were incubated with a 10-fold excess ofCTL (15). After immunoselection with
CTL 5/57, 13 survivor clones were found out of 105 initial cells plated at 103
cells/well (series A), and 17 surviving tumor cell clones were found out of 2 x 105
initial cells plated at 2 x 103 cells/well (series B). Two of the survivors, SK-MEL-
29.1.22 (out ofseries A) and -29.1.29 (out ofseries B) were resistant to the selecting
CTL5/57, as well as to all other CTL clones established so far. Lysability ofthese
A
r r
B C
1 2 3 4 1 2 3 4 1 2 3
serum dilution steps
CTL2/9
￿
CTL5/57
￿
CTL5/75
1 2 3 4 1 2 3 1 1 2 3 4
antibody dilution steps
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FIGURE 2.
￿
Inhibition of CTL lysis by human anti-HLA-A2
pregnancy serum. Serum(HbF-3423) was addedat astarting
dilution of 1:2 to thecytolysis assay (effector, CTL2/9; target,
SK-MEL-29.1; E/T, 30:1 for 4-h incubation; 0, no serum
added (A). Serum Bwas absorbed to PLHTR cells(untrans-
fected)and serumCto P1.HTRA2 (expressing HLA-A2 after
transfection) before thecytolysistest. Absorption was performed
by mixing 109 cells with 0.9 ml of serum and incubating the
suspension for 1 h at room temperature vigorously shaken at
regular intervals. Dots represent means of triplicates.
FIGURE 3.
￿
Inhibition of CTLlysis by anti-
HLA-A2 mAbs. Cytolysic activity of CTL
clones directed against three different tumor
antigens was tested in thepresence ofvarious
mAbs (target, SK-MEL-29.1; E/T, 30:1 ; for
4-hincubation). Antibodieswere addedin as-
citesform at astartingdilution of 1:100. (")
W6/32; (A)MA2.1; (A)PA2.1; (O) negative
control; (0) no antibody; for further infor-
mation about mAb see Table I).802
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FIGURE 4 .
￿
Cytolytic activity of
AVCTL clones againstimmu-
noselected tumor cell variants .
For information about target
melanoma clones see Fig. 1. CTL
inA were derived from MLTC
experiments with SK-MEL-
29.1 as stimulator. CTL7/147
(B)was derived in the course of
a MLTC experiment with SK-
MEL-29 .1.29 . Targets were pre-
treated with IFN-y (0) (100
U/ml for4 d) or untreated(O) .
tumor cell variants could not be restored by pretreatment with IFN-'y (Fig. 4A for
three of five CTL clones) . Since these two tumor cell variants behaved identically
in allCTL lysis tests and FRCS analyses described below, only the data obtained
with SK-MEL-29.1.29 are shown . SK-MEL-29 .1.22 and -29.1 .29 additionally lost
thegrowth-stimulating ability fortheCTLclones (not shown) . We performedaDNA
fingerprint analysis to demonstrate that the tumor cell variants resistant to lysis by
different autologous CTL specificities are ofthe same genetic origin as the parental
melanoma cell clone. The bacteriophage M13, generally used as a cloning vector
for DNA sequencing, was reported to hybridize to a distinct set of hypervariable
minisatellites in the genome ofa variety of species . It is used as a probe to detect
individual specific hybridization patterns in Southern blot analysis (39) . As shown
in Fig . 6, the patterns obtained withDNA from SK-MEL-29.1.22 and -29.1.29 cor-
respond to theparentalmelanoma cell cloneSK-MEL-29.1, to AVCTL clones, and
to the AV EBVB cells, indicating identical genetic origin . The hybridization pat-
terns of allogeneic cell lines could be clearly distinguished from AV cells .
According to the results described above, HLA-A2 is directly involved in the rec-
ognition ofthree differentAV melanoma antigens . Loss ofHLA-A2 expression shouldmonoclonal antibodies
￿
AV-melanoma
W6/32 MA2 .1 PAM N655
clones
(anti-NLAI) (anti-NLA-A2) (anti-NLAII) (±IFN-61
WOLFEL ET AL .
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S6-MEL-29 .1
FIGURE 5 . FACS analysis of
immunoselected AV melanoma
clones . For information about
the derivation of tumor cell
clones andabout antibodies see
Fig. 1 andTable 1, respectively .
Where indicated, tumor cells
were pretreated with IFN--f at
100 LJ/ml for4d . 5,000 stained
cells per sample were analyzed .
The fluorescence intensity is
displayed on alogarithmic scale
in channels .
then result in resistance to lysis by allCTL specificities . A FACS analysis was per-
formed on theimmunoselected variants (Fig . 5) . All themelanoma clones expressed
HLA class I molecules . However, the variant clones SK-MEL-29.1.22 (not shown)
and 1.29 didnot express HLA-A2 at a detectable level as tested withtwoanti-HLA-
A2 mAbs(MA2 .1 andPA2.1) binding to different epitopesonHLA-A2 (38) . Pretreat-
ment with IFN- ,y induced the expression ofHLA class II molecules and increased
the overall expression ofHLA class I molecules on all tumor cell clones, but did
FIGURE 6 .
￿
Fingerprint analysis with
bacteriophage M13DNA.DNAofvar-
ious cell lines was digested with Hinf
I (59), separated on a0.7% agarose gel,
transferred to nitrocellulose filters, and
hybridized with 32P-labeledM13DNA
according to reference 28. Lane 1,MZ-
2-MEL ; lane 2, AK-EBV; lane 3, AV
EBV ; lane 4, CTL2/9 ; lane 5, CTL5/
76 ; lane 6, SK-MEL-29.1 ; lane 7and
8, SK-MEL-29.1.22 and 1.29. Hind III
fragments ofXphageDNAwere used
as size markers (fragment lengths in
kilobases) .804
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not induce HLA-A2 expression on clones 1 .22 (not shown) and 1.29 . In addition,
IEF analysis ofHLAclass I antigens immunoprecipitated withW6/32 from the mela-
noma clone SK-MEL-29.1.29 confirmed the loss ofHLA-A2 expression . This mela-
noma clone also lacked expression of HLA-B44 without IFN treatment (Fig . 7) .
Cytofluorographic characteristics and the resistance to lysisby the HLA-A2-restricted
AVCTL clones were repeatedly controlled and found to be stable over a continued
culture period of 1 yr.
Derivation ofAVCTL Clones that Involve an HLA-B Molecule in Lysis ofAutologous Tumor
Cells; Impact ofIFN-y on their Lytic Activity. To find out whether additional HLA
molecules are involved in autologous target recognition, MLTC experiments were
performed withAVPBL andtheautologous variant melanomacloneSK-MEL-29.1.29,
which did not express HLA-A2 . Responder lymphocytes were cloned after 7 d . Of
1,000 wells seeded at one responder cell per well, 156 proliferating clones were ob-
tained . Among 15 responder clones with lytic activity, eight clones lysed SK-MEL-
29 .1.29 but not K562 and not autologous EBVtransformedB cells . Two fast growing
CTL clones, CTL7/4 and CTL7/147, were chosen for further studies .
In repeated tests both CTL clones lysed SK-MEL-29.1.29 cells only weakly. The
specific "Crreleases did not exceed 255 Io at an E/T ratio of 30:1 . However, pretreat-
ment oftumor cells with IFN-y restored the lysisin a dose-dependent manner. Op-
timal lysis was seen at an IFNconcentration of 100U/ml for4d in tumor cell culture
medium . K562 andAV EBV cells remained resistant to lysis afterexposure to IFN.
The HLA-A2+ AV melanoma clones SK-MEL-29.1 and -29.1.14 were only effec-
tively lysed after exposure to IFN-y . This indicated that the low level of expression
ofthe target structure(s) recognized by the newly establishedCTLclones isacommon
trait of SK-MEL-29 cells . Fig. 4 B summarizes the lysis ofAV melanoma clones .
Only the results obtained withCTL7/147 are shown since both CTL behaved iden-
tically in all tests .
The tumor cell variant SK-MEL-29.1.109, which is negative for the CTL-defined
antigen A, wasresistant to lysis by both CTL, even after pretreatment with IFN-y .
One explanation is that antigenA is presented to autologous CTL both in associa-
FIGURE 7 .
￿
IEF analysis of immunoprecipitates from AV
melanoma clones . Immunoprecipitation was performed with
themAb W6/32 (16) . The fluorograph ofthe gel isoriented
with the basic end at the top. Samples are lane 1, AVEBV;
lane 2, SK-MEL-29 .1 ; lane 3, SK-MEL-29 .1.29 .HLA-A2
TABLE II
Involvement of Different Class I Molecules in the Recognition of SK-MEL-29 Cells
by Autologous CTL Clones as Indicated by Inhibition of Cytolysis
Antibodies were used in ascites form at a 1 :100 dilution in a 4-h 51Cr release assay (E/T, 30:1).
As target we used SK-MEL-29.1 pretreated with IFN-y at 100 U/ml for4 d. Data are percent
specific 5'Cr release. Antigenic specificities of antibodies are indicated in Table I.
845
FtauRE 8.
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Diagram ofCTL-defined antigens and HLA restriction ele-
ments on AV melanoma cells as deduced from antibody inhibition and
selection experiments.
tion with HLA-A2 and with an HLA-B molecule (Fig. 7). Alternatively, however
less likely, the tumor cell clone SK-MEL-29.1.109 may have lost the expression of
both antigen A and the respective HLA-B-molecule. Our present effort to identify
the HLA-B-molecule involved in CTL recognition will perhaps answer this ques-
tion. Lysis of IFN-treated SK-MEL-29.1 cells by CTL7/4 and CTL7/147 was in-
hibited by W6/32. Anti-HLA-A2 mAb had no effect. The mAb 4E (25), however,
which is directed against a common HLA-B determinant, could inhibit CTL lysis,
whereas this antibody had no effect on the lysis by HLA-A2-restricted CTL (Table
II). The mAb 4E also blocked the lysis by CTL7/4 and 7/147 on IFN-treated SK-
MEL-29.1.29 cells (not shown). The observation that MA2.1 could not inhibit lysis
by these newly established CTL on an HLA-A2' target formally excluded a
nonspecific inhibition of lysis by the previously established CTL.
Discussion
In the human melanoma SK-MEL-29 (AV), at least three different antigens are
recognized by autologous CTL in association with HLA-A2 (Fig. 8). Four HLA-
A2' allogeneic melanoma lines included in a specificity analysis were found to be
resistent to lysis by AV CTL (15). This indicates that the expression o£ these tumor
antigens is not common in human melanoma. In a study on human sarcomas a
common antigen was reported to be recognized by CTL in association with HLA-
A2 (40).
CTL clone
Without
antibody W6/32 HB55 MA2.1 PA2.1 4E NS-1
CTL2/9 66 0 65 3 i l 68 55
CTL5/57 84 11 85 15 55 89 85
L7/4 70 0 74 68 68 0 82
L7/147 52 0 46 49 54 0 53806
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HLA-restricted virus-specific CTL were shown to react with synthetic peptides
of viral antigens bound to appropriate HLA molecules on uninfected target cells
(12). This observation implies that CTL recognize viral antigens after processing
to peptide fragments and association with MHC molecules. Pointmutations of HLA-
A2 were suggested to impair CTL recognition by interfering with peptide binding,
altering the position of the respective peptide or changing the conformation of the
peptide-HLA complex (41). In our previous experiments, AV melanoma variant clones
were derived after mutagenesis and immunoselection that were only resistant to lysis
by the selecting CTL clone. This was suggested to be due to loss of expression of
certain tumorantigens (15). Regarding the findings reported here, however, it cannot
be ruled out that mutations of the restricting HLA-A2 molecule that are undetect-
able by antibody binding might have occurred in "antigen loss" variants. Such muta-
tions could affect tumor antigen binding and, thus, account for resistance of variant
tumor cell clones to CTL lysis.
All AV CTL clones previouslyestablished in the course ofthree independent MLTC
experiments with SK-MEL-29.1 stimulatorcells are restricted by HLA-A2. AV CTL
(CTL7/4 and 7/147) that do not depend on HLA-A2 for the recognition of autolo-
gous target cells were only derived by MLTC with the HLA-A2 - melanoma clone
1.29. These CTL clones exhibit strong lytic activity when target cells are pretreated
with IFN-y, which is known to induce HLA class I and II expression on human
melanoma cells (42, 43). As indicated by antibody inhibitionexperiments, an HLA-
B molecule is involved in target recognition by CTL7/4 and CTL7/147 . On SK-
MEL-29 cells the HLA-B locus is weakly expressed as compared with the HLA-A
locus, and HLA-B expression can be strongly enhanced by IFN-y (unpublished
results). Thus, the differential expression ofHLA subregions can explain why HLA-A2
appears to be a dominant restriction element on SK-MEL-29 cells.
The importance of MHC restriction elements both for recognition by immune
effectors in vitro and for progression of the tumors in vivo is well documented in
several rodent tumor models (for review see reference 44). In human cancer, lacking
or strongly reduced HLA class I expression was found in small cell lung carcinoma
(45), neuroblastoma (46), mammary carcinoma (47, 48), skin carcinomas (49, 50),
colorectal carcinoma (51), and B cell lymphoma (52). For the latter three a correla-
tion between low class I expression and histologic criteria ofmalignancy was shown.
Melanoma metastases frequently express HLA class I molecules at lower levels than
the respectiveprimary tumors (53, 54). Downmodulation ofHLA class I expression
in melanomas as well as in neuroblastomas seems to be correlated in vitro with high
levels of myc oncogene expression, which can be reversed by IFN-y (55, 56). While
all these observations concern pan-HLA class I expression on human tumors, there
is so far little evidence for reduced or lacking expression of HLA subregions (57,
58). In the AV melanoma model we observed the loss of the product of a single HLA
class I allele that presents multiple tumorantigens to autologous CTL. Such events
may have an impact on tumor progression in vivo. The use of antibodies against
locus- and allele-specific HLA determinants should help to evaluate in immuno-
histochemical studies whether loss of single HLA specificities occurs in vivo in
metastatic disease.
Summary
From the peripheral blood of the melanoma patient (AV), we derived cytolyticWOLFEL ET AL.
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T lymphocyte (CTL) clones that lysed the autologous tumor line SK-MEL-29, but
not autologous EBVB cells, K562, and other tumor targets. By immunoselection
experiments it was shown that the CTL clones recognized at least three different
antigens on the autologous tumorcells. We demonstrate here that these melanoma
antigens are presented to the CTL in association with HLA-A2. First, HLA-A2-
reactive pregnancy sera as well as an mAb against HLA-A2 inhibited the CTL lysis.
Second, immunoselected melanoma subclones that were resistant to lysis by CTL
clones against the three antigens described were found to lack expression of HLA-
A2. By sensitizing the patient's lymphocytes against an HLA-A2- melanoma clone,
we established a new series of CTL clones recognizing autologous AV melanoma
cells. However, efficient lysis was only seen when target cells were pretreated with
IFN-.y. The lytic activity ofthese CTL was selectively inhibited by an mAb against
a common HLA-B determinant. These results indicate that in addition to HLA-A2,
other class I antigens are involved in the recognition of AV melanoma cells by autol-
ogous CTL.
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